Tumor antigens are constitutively presented in the draining lymph nodes

Journal of Immunology

Volumn 162, Issue 10, 1999, Pages 5838-5845

  Marzo, Amanda L ^a   Lake, Richard A ^a   Lo, David ^b   Sherman, Linda ^b   McWilliam, Andrew ^c   Nelson, Delia ^a   Robinson, Bruce W S ^a   Scott, Bernadette ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 CARBOXYFLUORESCEIN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CLONE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; INOCULATION; LYMPH NODE; MITOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0033563121     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Onrust, S. V., P. M. Hartl, S. D. Rosen, and D. Hanahan. 1996. Modulation of L-selectin ligand expression during an immune response accompanying tumori-genesis in transgenic mice. J. Clin. Invest. 97:54.
2. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
3. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
4. + T cells by B7-transfected melanoma cells. Science 259:368.
5. Leong, C., J. Marley, S. Loh, B. Robinson, and M. Garlepp. 1996. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression. Cancer Gene Ther. 3:321.
6. Cohen, E. P., and T. S. Kim. 1994. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 5:419.
7. Cromme, F. V., J. Airey, M. T. Heemels, H. L. Ploegh, P. J. Keating, P. L. Stem, C. J. Meijer, and J. M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335.
8. Garrido, F., T. Cabrera, N. M. Lopez, and C. F. Ruiz. 1995. HLA class I antigens in human tumors. Adv. Cancer Res. 67:155.
9. Seliger, B., M. J. Maeurer, and S. Ferrone. 1997. TAP off - tumors on. Immunol. Today 18:292.
10. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
11. Ranges, G. E., I. S. Figari, T. Espevik, and M. J. Palladino. 1987. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166:991.
12. Torre, A. G., R. D. Beauchamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses, and D. A. Rowley. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87:1486.
13. Becker, J. C., C. Czerny, and E. B. Brocker. 1994. Maintenance of clonal anergy by endogenously produced IL-10. Int. Immunol. 6:1605.
14. Matsuda, M., F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q. J. Zhang, M. G. Masucci, and R. Kiessling. 1994. Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and down-regulates HLA class I expression. J. Exp. Med. 180:2371.
15. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
16. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
17. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1361.
18. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Borland, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
19. Walker, P. R., P. Saas, and P. Y. Dietrich. 1991. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 158:4521.
20. Chen, L. 1998. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 19:27.
21. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, F. K. McKall, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
22. + T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157:978.
23. Scott, B., R. Liblau, S. Degermann, L. A. Marconi, L. Ogata, A. J. Caton, H. O. McDevitt, and D. Lo. 1994. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1:73.
24. Davis, M. R., L. S. Manning, D. Whitaker, M. J. Garlepp, and B. W. Robinson. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52:881.
25. Leong, C. C., J. V. Marley, S. Loh, B. W. Robinson, and M. J. Garlepp. 1997. The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. Immunol. Cell Biol. 75:356.
26. Marzo, A. L., R. A. Lake, B. W. Robinson, and B. Scott. 1999. TCR transgenic analysis of tumor specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59:1021.
27. + T cells. Eur. J. Immunol. 22:1013.
28. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131.
29. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184:923.
30. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Bone marrow-derived cells present MHC class I-restricted rumour antigens in priming of antitumour immune responses. Ciba Found. Symp. 187:229.
31. Hermans, I. F., A. Daish, J. Yang, D. S. Ritchie, and F. Ronchese. 1998. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res. 58:3909.
32. Caminschi, I., E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. Scott, and B. W. S. Robinson. 1998. Interleukin-12 induces an effective anti-tumor response in malignant mesothelioma. Am. J. Respir. Cell Mol. Biol. 19:1.
33. Gray, D., and H. Skarvall. 1988. B-cell memory is short-lived in the absence of antigen. Nature 336:70.
34. Gray, D., and P. Matzinger. 1991. T cell memory is short-lived in the absence of antigen. J. Exp. Med. 174:969.
35. Kundig, T. M., M. F. Bachmann, P. S. Ohashi, H. Pircher, H. Hengartner, and R. M. Zinkernagel. 1996. On T cell memory: arguments for antigen dependence. Immunol. Rev. 150:63.
36. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186: 2057.
37. Santin, A. D., and G. P. Parham. 1998. Routine lymph node dissection in the treatment of early stage cancer: are we doing the right thing? Gynecol. Oncol. 68:1.
38. Curry, B. J., K. Myers, and P. Mersey. 1998. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J. Clin. Oncol. 16:1760.